Creating a vaccine to generate antibodies against HIV
Official title: Eliciting Broadly Neutralizing Antibody Responses against HIV-1 Fusion Peptide Epitope by AB Toxin B Subunit-Based Immunogens
Funded at New York University School of Medicine · NIH-11009295 · Data updated 2026-11-12
This study is testing a new vaccine designed to help your immune system fight HIV by targeting a specific part of the virus, and it’s for anyone interested in helping improve treatments for HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 2, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $859,597 |
| NIH project number | 1R01AI181676-01A1 |
| Project ID | NIH-11009295 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals at high risk for HIV infection or those living with HIV who are seeking new treatment options.
✕Less likely to help
Patients who are not at risk for HIV or those who are already receiving effective treatment may not benefit from this research.
What this research studies
This research focuses on developing a vaccine that targets a specific part of the HIV virus known as the fusion peptide to stimulate the immune system to produce broadly neutralizing antibodies (bnAbs). The approach involves using a fusion immunogen made from the fusion peptide and cholera toxin subunit B, which has shown promise in animal studies for eliciting strong antibody responses. By combining this immunogen with a booster vaccine, the goal is to achieve a robust and effective immune response against various strains of HIV. If successful, this vaccine could significantly enhance the body's ability to fight HIV infection.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking vaccine that provides effective protection against HIV.
How similar studies have gone: Previous studies using similar immunogen approaches have shown promising results in animal models, indicating potential for success in human trials.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Kong, Xiangpeng — New York University School of Medicine
- Study coordinator: Kong, Xiangpeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.